Richard Wooster Net Worth

Richard Wooster biography

Dr. Richard Wooster Ph.D. serves as Chief Scientific Officer of the Company. He has served as our chief scientific officer since April 2019. From March 2015 to April 2019, Dr. Wooster served as the president of research and development and chief scientific officer at Tarveda Therapeutics, Inc., a biopharmaceutical company (formerly known as Blend Therapeutics, Inc.). From May 2013 until March 2015, he acted as the chief scientific officer of Tarveda Therapeutics and as its president from January 2014 to March 2015. Prior to joining Tarveda Therapeutics, Dr. Wooster was vice president and discovery performance unit head in oncology at GlaxoSmithKline plc, a pharmaceutical company. During his academic career, Dr. Wooster discovered the breast cancer susceptibility gene BRCA2, was one of the founders of the Cancer Genome Project at the Welcome Trust Sanger Institute where mutations in BRAF were first discovered and developed the COSMIC mutation database and website. He has more than 100 peer-reviewed articles and papers in scientific journals. Dr. Wooster received a BSc in Biochemistry and a Ph.D. in drug metabolizing enzymes from the University of Dundee, Scotland.

What is the salary of Richard Wooster?

As the Chief Scientific Officer of Telesis Bio Inc, the total compensation of Richard Wooster at Telesis Bio Inc is $2,633,950. There are 1 executives at Telesis Bio Inc getting paid more, with Ronald Renaud having the highest compensation of $3,386,150.

How old is Richard Wooster?

Richard Wooster is 55, he's been the Chief Scientific Officer of Telesis Bio Inc since 2019. There are 6 older and 7 younger executives at Telesis Bio Inc. The oldest executive at Telesis Bio Inc is Jean-Francois Formela, 63, who is the Independent Director.

What's Richard Wooster's mailing address?

Richard's mailing address filed with the SEC is C/O TRANSLATE BIO, INC., 29 HARTWELL AVE, LEXINGTON, MA, 02421.

Insiders trading at Telesis Bio Inc

Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk und Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.

What does Telesis Bio Inc do?

sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.

Telesis Bio Inc executives and stock owners

Telesis Bio Inc executives and other stock owners filed with the SEC include:

• Ronald Renaud,
  President, Chief Executive Officer, Director
• Richard Wooster,
  Chief Scientific Officer
• John Schroer,
  Chief Financial Officer, Treasurer
• Brian Fenton,
  Chief Business Officer
• Robert Plenge,
  Independent Director
• Robert Meyer,
  Independent Director
• George Demetri,
  Independent Director
• Daniel Lynch,
  Independent Chairman of the Board
• Daniella Beckman,
  Independent Director
• Owen Hughes,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Ann Barbier,
  Chief Medical Officer
• Frank DeRosa,
  Chief Technology Officer
• Paula Cloghessy,
  Chief Human Resource Officer
• Paul Burgess,
  Chief Operating Officer, Chief Legal Officer
• Michael Heartlein,
  Founder, Executive Vice President
• Paul M Meister,
  Director
• Everett Rand Sutherland,
  President
• Brian M. Jr. Gallagher,
  Director
• Ventures Fund Llc Mrl,
  10% owner
• Venture Fund Viii, L.P.Atla...,
  
• Plc Gsk,
  10% owner
• Human Genetic Therapies, In...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• James B Weissman,
  
• Michael R. Hodges,
  
• Todd Krueger,
  
• Steven J Golub,
  
• Sarah E. Hlavinka,
  
• Daniel Glenn Gibson,
  Chief Technology Officer
• Human Genetic Therapies, In...,
  
• Group Llc/Ma Baupost Group ...,
  
• Brendan Smith,
  Chief Financial Officer
• Sanofi,
  10% owner
• Ventures Gp, Llc Northpond ...,
  
• Fund Iv, Llc Broad Oak,
  10% owner
• William Snider,
  Director
• William J Kullback,
  Chief Financial Officer
• Rob Cutler,
  Chief Legal Officer
• Todd Robert Nelson,
  Chief Executive Officer
• Eric Eugene Esser,
  President & CEO
• Frank Witney,
  
• Christine A Tsingos,
  
• Annette Tumolo,
  
• Gregory J. Herrema,
  
• Jami K Nachtsheim,